Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-13
2010-06-08
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S089000
Reexamination Certificate
active
07732459
ABSTRACT:
The invention provides compounds having the formula:wherein R1is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
REFERENCES:
patent: 3409621 (1968-11-01), Villani eral.
patent: 3770729 (1973-11-01), Nakanishi et al.
patent: 4042695 (1977-08-01), Buss
patent: 4250176 (1981-02-01), Vandenberk et al.
patent: 4335122 (1982-06-01), McFadden et al.
patent: 4547496 (1985-10-01), Kumazawa et al.
patent: 4567178 (1986-01-01), Eberlein et al.
patent: 4645758 (1987-02-01), Willman et al.
patent: 4994463 (1991-02-01), Oshima et al.
patent: 4999363 (1991-03-01), Oshima et al.
patent: 5010087 (1991-04-01), Oshima et al.
patent: 5010104 (1991-04-01), Oshima et al.
patent: 5011836 (1991-04-01), Eberlein et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5116863 (1992-05-01), Ohshima et al.
patent: 5118701 (1992-06-01), Oshima et al.
patent: 5143922 (1992-09-01), Oshima et al.
patent: 5239083 (1993-08-01), Kumazawa et al.
patent: 5242931 (1993-09-01), Oshima et al.
patent: 5302596 (1994-04-01), Oshima et al.
patent: 5302602 (1994-04-01), Oshima et al.
patent: 5340807 (1994-08-01), Kumazawa et al.
patent: 5378701 (1995-01-01), Ohshima et al.
patent: 5478835 (1995-12-01), Kumazawa et al.
patent: 5478840 (1995-12-01), Oshima et al.
patent: 5538986 (1996-07-01), Ting et al.
patent: 5607955 (1997-03-01), Oshima et al.
patent: 5672611 (1997-09-01), Doll et al.
patent: 5679703 (1997-10-01), Yanase et al.
patent: 5688788 (1997-11-01), Andersen et al.
patent: 5801175 (1998-09-01), Afonso et al.
patent: 5874428 (1999-02-01), Dorwald
patent: 5877177 (1999-03-01), Taveras
patent: 5919776 (1999-07-01), Hagmann
patent: 6040318 (2000-03-01), Andersen et al.
patent: 6048856 (2000-04-01), Jørgensen et al.
patent: 6150355 (2000-11-01), Kumazawa et al.
patent: 6281212 (2001-08-01), Schwender et al.
patent: 6288083 (2001-09-01), Luly et al.
patent: 6288084 (2001-09-01), Luly et al.
patent: 6323206 (2001-11-01), Schwender et al.
patent: 6329385 (2001-12-01), Luly et al.
patent: 6433165 (2002-08-01), Luly et al.
patent: 6503926 (2003-01-01), Luly et al.
patent: 6509346 (2003-01-01), Luly et al.
patent: 6613905 (2003-09-01), Luly et al.
patent: 2002/0169155 (2002-11-01), Luly et al.
patent: 2003/0045516 (2003-03-01), Luly et al.
patent: 2005/0070549 (2005-03-01), Luly et al.
patent: 421 138 (1967-03-01), None
patent: 236549 (1985-05-01), None
patent: 236550 (1985-05-01), None
patent: 240 698 (1987-06-01), None
patent: 80449 (1969-09-01), None
patent: 1 918 739 (1969-10-01), None
patent: 33 26 641 (1984-02-01), None
patent: 0 235 796 (1987-09-01), None
patent: 0 270 692 (1988-06-01), None
patent: 0 325 755 (1989-02-01), None
patent: 0 309 422 (1989-03-01), None
patent: 0 341 860 (1989-11-01), None
patent: 0 515 158 (1992-11-01), None
patent: 0 524 784 (1993-01-01), None
patent: 0 916 668 (1999-05-01), None
patent: 1 003 292 (1965-09-01), None
patent: 1 003 950 (1965-09-01), None
patent: 1 013 574 (1965-12-01), None
patent: 1 085 406 (1967-10-01), None
patent: 1109847 (1968-04-01), None
patent: 1 206 216 (1970-09-01), None
patent: 1213172 (1970-11-01), None
patent: 1 330 966 (1973-09-01), None
patent: 1 347 935 (1974-02-01), None
patent: 61 167663 (1986-07-01), None
patent: 9-40662 (1997-02-01), None
patent: WO 89/10369 (1989-11-01), None
patent: WO 92/16226 (1992-10-01), None
patent: WO 92/20681 (1992-11-01), None
patent: WO 93/02081 (1993-02-01), None
patent: WO 96/31469 (1996-10-01), None
patent: WO 96/31470 (1996-10-01), None
patent: WO 96/31477 (1996-10-01), None
patent: WO 96/31498 (1996-10-01), None
patent: WO 97/24325 (1997-07-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/04554 (1998-02-01), None
patent: WO 98/11092 (1998-03-01), None
patent: WO 98/11093 (1998-03-01), None
patent: WO 98/11096 (1998-03-01), None
patent: WO 98/11097 (1998-03-01), None
patent: WO 98/11098 (1998-03-01), None
patent: WO 98/11099 (1998-03-01), None
patent: WO 98/11106 (1998-03-01), None
patent: WO 98/15546 (1998-04-01), None
patent: WO 98/25604 (1998-06-01), None
patent: WO 98/25605 (1998-06-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 98/27815 (1998-07-01), None
patent: WO 98/43638 (1998-10-01), None
patent: WO 98/46587 (1998-10-01), None
patent: WO 99/37617 (1999-07-01), None
patent: WO 99/37619 (1999-07-01), None
patent: WO 99/37651 (1999-07-01), None
patent: WO 00/14086 (2000-03-01), None
patent: WO 00/14089 (2000-03-01), None
patent: WO 00/32193 (2000-06-01), None
patent: WO 01/09094 (2001-02-01), None
patent: WO 01/09119 (2001-02-01), None
patent: WO 01/09137 (2001-02-01), None
patent: WO 01/09138 (2001-02-01), None
patent: WO 03/045942 (2003-06-01), None
Cutolo et al., Journal of cellular biochemistry, (Aug. 21-Sep. 5, 2001) vol. 83, No. 3, pp. 390-400.
Davis, M. A., et al., “New Psychotropic Agents.VIII Analogs of Amitriptyline Containing Normeperidine Group,”J. Med. Chem., 10:627-635 (1967).
Helwig, H., et al.,“Helwig/Otto Arzneimittal, Ein Handbuch fur Arzte und Apotheker”, pp. 4-1 through 4-24, 8th Ed., (1992).
Sindelar, Karel, et al., “Potential Antidiarrheal Agents:1-(11-Cyano-6,11-Dihydrodibenzo[b, e]Thiepin-11yl-Alkly1)- and 1-(10-cyano-10,11-Dihydrodibenzo[bf]Thiepin-10-YL-Alky1)-4-Substituted Piperidines,”Collection Czechoslovak Chem. Commun.50:1089-1096 (1985).
Sindelar, K., et al., Chemical Abstracts, 121:35275n (1994).
Sindelar, Karel, et al., “Antihistamine Substances: Tricyclic Analogues ofN-(4,4-Diphenyl-3Butene-1YL)Nipecotic Acid and Some Related Compounds,”Collection Czechoslovak Chem. Commun.59:667-674 (1994).
Ali, Fadia E., et al., “Orally Active and Potent Inhibitors of γ-Aminobutyric Acid Uptake,”J. Med. Chem.28:653-660 (1985).
Sindelar, Karel, et al., “Potential Antihistaminics: Tricyclic Carboxylic Acids Derived from 6,11-Dihydrodibenzo[b,e]Thiepine and 4,9-Dihydrothieno[2,3-c]-2-Benzothiepine,”Collection Czechoslovak Chem. Commun.56:2482-2493 (1991).
Polivka, Zdenek, et al., “Heterocyclic Ethers Derived from 6,11-Dihydrodibenzo-[b,e]Thiepin-11-ols and 4,9-Dihydrothieno[2,3-c]-2-Benzothiepin-4-ol; A New Series of Potential Antidepressants and Antihistamine Agents,”Collection Czechoslovak Chem. Commun.51:2034-2049 (1986).
Polivka, Zdenek, et al., “Antiaminic Agents Derived from Thieno[2,3-c]-2-Benzothiepin: 4-(1-Methyl-4-Piperidylidene)-4,9-Dihydrothieno[2,3-c]-2-Benzothiepin and some Related Compounds,”Collection Czechoslovak Chem. Commun.48:623-641 (1983).
Rajsner, M., et al., “Neurotropic and Psychotropic Compounds. XXXI Chemistry and Pharmacology of 11-(3-Dimethylaminopropylidene)-2-Mehtyl-6,11-Dihydrodibenzo[b, e] Thiepin and of Some Analogues,”Collection Czechoslovak Chem. Commun.34:1015-1024 (1969).
Rajsner, M., et al., “Neurotrope and Psychotrope Substanzen XV. 4,9-Dihydrothieno[2,3-b]Benzo[e]Thiepin-Derivate,”Collection Czechoslovak Chem. Commun.32:2854-2866 (1967).
Hesselgesser, Joseph, et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor”,The Journal of Biological Chemistry, 273(25):15687-15692 (1998).
Masaru, E. et al., Chemical Abstracts, 93(19), 186323f (1980).
Tsujikawa, T. et al., Chemical Abstracts, 77(25), 164662h (1972).
Nakanishi, M. et al. Chemical Abstracts, 81:25566Z (1974).
Ting, P.C. et al., Chemical Abstracts, 123:227838 (1995).
Kumazawa, T. et al., Chemical Abstracts, 126:212158 (1997).
Kato, K. et al., Chemical Abstracts, 130:237480 (1999).
Davis, M.A. et al., Chemical Abstracts, 67:99959 (1967).
Kukla, Michael J., Chemical Abstracts, 92:198282 (1980).
Protiva, M. et al., Chemical Abstracts, 72:3387 (1970).
Protiva, M. et al., Chemical Abstracts, 109:92794 (1988).
Protiva, M. et al., Chemical Abstracts, 104:19527 (1986).
Protiva, M. et al., Chemical Abstracts
Carson Kenneth G.
Ghosh Shomir
Harriman Geraldine C. B.
McDermott Will & Emery LLP
Millennium Pharmaceuticals Inc.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
CCR1 antagonists and methods of use therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCR1 antagonists and methods of use therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR1 antagonists and methods of use therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243939